Proteasome inhibitors as therapeutics.
暂无分享,去创建一个
[1] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[2] A. Zelenetz,et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Michael L. Wang,et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] D. Esseltine,et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma , 2004, British journal of haematology.
[5] L. Schwartz,et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Grever,et al. Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors , 2004, Clinical Cancer Research.
[7] K. Kelly,et al. Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Preliminary results , 2004 .
[8] Steven W. Johnson,et al. Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial , 2004 .
[9] P. Sonneveld,et al. Bortezomib vs. dexamethasone in relapsed multiple myeloma: A phase 3 randomized study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] D. Esseltine,et al. Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Hossfeld,et al. Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] H. Lenz,et al. Bortezomib ± irinotecan in relapsed/refractory colorectal cancer (CRC): Interim analysis results from phase (ph) 2b study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Millikan,et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E. Estey,et al. Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias , 2004, Clinical Cancer Research.
[15] J. Adams. The development of proteasome inhibitors as anticancer drugs. , 2004, Cancer cell.
[16] J. Adams. The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.
[17] E. Vokes,et al. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Neal N. Iwakoshi,et al. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[19] L. Pham,et al. Inhibition of Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis1 , 2003, The Journal of Immunology.
[20] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[21] K. Anderson,et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. , 2003, Blood.
[22] D. Howard,et al. Preferential induction of apoptosis for primary human leukemic stem cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[23] Beverly S Mitchell,et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] T. Libermann,et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[25] Masaharu Akiyama,et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications , 2002, Oncogene.
[26] S. Soignet,et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] N. Munshi,et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. , 2002, Blood.
[28] N. Munshi,et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. , 2002, Blood.
[29] JB Almond,et al. The proteasome: a novel target for cancer chemotherapy , 2002, Leukemia.
[30] N. Mitsiades,et al. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. , 2002, Blood.
[31] J. Adams. Development of the proteasome inhibitor PS-341. , 2002, The oncologist.
[32] N. Mitsiades,et al. Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias , 2001, Expert opinion on investigational drugs.
[33] P. Elliott,et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer , 2001, Journal of cellular biochemistry.
[34] P. Elliott,et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. , 2001, Cancer research.
[35] P. Elliott,et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.
[36] C. Watson,et al. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells , 2001, Cell Death and Differentiation.
[37] A. Goldberg,et al. Proteasome inhibitors: from research tools to drug candidates. , 2001, Chemistry & biology.
[38] P. Elliott,et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] H. Magdelenat,et al. Ubiquitin-Proteasome System and Increased Sensitivity of B-CLL Lymphocytes to Apoptotic Death Activation , 2000, Leukemia & lymphoma.
[40] W. Risau,et al. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[41] R. Herbst,et al. The proteasome inhibitor PS-341 in cancer therapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[42] C. Slaughter,et al. The Proteasome, a Novel Protease Regulated by Multiple Mechanisms* , 1999, The Journal of Biological Chemistry.
[43] S Omura,et al. Increased sensitivity of CLL‐derived lymphocytes to apoptotic death activation by the proteasome‐specific inhibitor lactacystin , 1999, British journal of haematology.
[44] E. Sausville,et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.
[45] M. Grever,et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. , 1998, Cancer research.
[46] L. Dick,et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. , 1998, Bioorganic & medicinal chemistry letters.
[47] A. Goldberg,et al. New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. , 1997, Biological chemistry.
[48] H. Drexler. Activation of the cell death program by inhibition of proteasome function. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[49] T. Libermann,et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. , 1996, Blood.
[50] Aaron Ciechanover,et al. The ubiquitin-proteasome proteolytic pathway , 1994, Cell.
[51] Tom Maniatis,et al. The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB , 1994, Cell.
[52] A. Goldberg,et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. , 1994, Cell.
[53] L. Zon,et al. Role of interleukin 6 in the growth of myelomaderived cell lines , 1992 .
[54] L. Zon,et al. Role of interleukin 6 in the growth of myeloma-derived cell lines. , 1992, Leukemia research.